Jeff Kindler's tenure as the CEO of pharmaceutical giant Pfizer was marked by sagging stock prices, a dried-up pipeline, and unexpected changes in strategy, capped by a "coup" of sorts that ultimately cost Kindler his job, reports Fortune magazine. The CEO was called to the airport in Fort Myers, Fla., on December 4, 2010, to "plead for his job" in front of three of the company's board members, write Fortune's Peter Elkind, Jennifer Reingold, and Doris Burke.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.